Article: Pension Fund Drops Suit Against Tesla Over $1.8B Bond Offer

Article - Media, Publications

Pension Fund Drops Suit Against Tesla Over $1.8B Bond Offer

Rachel Stone, 16 April 2021

A pension fund voluntarily ended its proposed class action against Tesla and its multibillionaire founder, Elon Musk, which claimed the automaker and a group of big banks acting as underwriters misled investors on a $1.8 billion bond offering.

Inter-Local Pension Fund GCC/IBT has bowed out of its securities fraud suit in California federal court following a decision in the Ninth Circuit in March not to rehear a related case, according to a notice filed Thursday. Continue reading “Article: Pension Fund Drops Suit Against Tesla Over $1.8B Bond Offer”

Fined: RBC Capital Markets, LLC Fined by FINRA

Fined

RBC Capital Markets, LLC Fined by FINRA

An AWC was issued in which the firm was censured, fined $2,900,000 and required to provide a written certification to FINRA that it has established and implemented a supervisory system and written procedures reasonably designed to achieve compliance with FINRA rules and the federal securities laws applicable to prospectus delivery. Without admitting or denying the findings, the firm consented to the sanctions and to the entry of findings that it failed to establish and maintain a reasonable supervisory system governing the delivery of prospectuses for exchange-traded funds (ETFs), exchangetraded notes (ETNs) and mutual funds and failed to enforce its WSPs.

Read full report.

 

Article: Benitec: The Health Payer’s Dream Biotech

Article - Media, Publications

Benitec: The Health Payer’s Dream Biotech

Pannobhaso, 12 March 2014

When it comes to forecasting the size of the market for drugs to treat various diseases, the estimates for the same disease can seem to fluctuated wildly depending on the model used and the timeframe of the forecast. However, one thing that is fairly consistent is that for many of the major diseases, these forecasts involve big numbers – billions of dollars. However, as a guide to pharmaceutical earnings, these forecasts are meaningless if health payers cannot afford the costs. Continue reading “Article: Benitec: The Health Payer’s Dream Biotech”